Dianthus Therapeutics (NASDAQ:DNTH) Sees Strong Trading Volume – Still a Buy?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) saw unusually-strong trading volume on Wednesday . Approximately 520,306 shares changed hands during mid-day trading, an increase of 113% from the previous session’s volume of 244,454 shares.The stock last traded at $17.54 and had previously closed at $16.83.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. TD Cowen began coverage on Dianthus Therapeutics in a report on Friday, December 20th. They set a “buy” rating on the stock. Raymond James upgraded shares of Dianthus Therapeutics to a “moderate buy” rating in a report on Thursday, December 12th. Guggenheim restated a “buy” rating and set a $84.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. HC Wainwright reiterated a “buy” rating and issued a $40.00 price objective on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Finally, Wedbush reissued an “outperform” rating and set a $36.00 target price on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $54.33.

Dianthus Therapeutics Trading Up 4.1 %

The company has a market capitalization of $562.67 million, a PE ratio of -7.05 and a beta of 1.82. The business has a fifty day moving average of $21.78 and a 200 day moving average of $24.09.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings data on Tuesday, March 11th. The company reported ($0.81) EPS for the quarter, beating the consensus estimate of ($0.85) by $0.04. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The business had revenue of $1.33 million during the quarter, compared to analyst estimates of $1.40 million. Equities analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Hedge Funds Weigh In On Dianthus Therapeutics

Several institutional investors have recently modified their holdings of DNTH. Wellington Management Group LLP boosted its holdings in Dianthus Therapeutics by 12.2% in the fourth quarter. Wellington Management Group LLP now owns 60,337 shares of the company’s stock valued at $1,315,000 after purchasing an additional 6,552 shares during the period. Woodline Partners LP boosted its stake in shares of Dianthus Therapeutics by 20.0% in the 4th quarter. Woodline Partners LP now owns 300,504 shares of the company’s stock valued at $6,551,000 after buying an additional 50,000 shares during the period. Vestal Point Capital LP grew its position in shares of Dianthus Therapeutics by 172.2% during the fourth quarter. Vestal Point Capital LP now owns 1,075,000 shares of the company’s stock worth $23,435,000 after buying an additional 680,000 shares in the last quarter. Octagon Capital Advisors LP increased its stake in shares of Dianthus Therapeutics by 20.8% during the fourth quarter. Octagon Capital Advisors LP now owns 2,110,167 shares of the company’s stock worth $46,002,000 after buying an additional 363,500 shares during the period. Finally, Millennium Management LLC raised its holdings in Dianthus Therapeutics by 160.2% in the fourth quarter. Millennium Management LLC now owns 90,436 shares of the company’s stock valued at $1,972,000 after acquiring an additional 55,682 shares in the last quarter. Institutional investors and hedge funds own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.